Compare abrdn Income Credit Strategies Fund (ACP) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs Cytokinetics Inc — how do they compare? abrdn Income Credit Strategies Fund trades at $5.23 (market cap $656.21M), while Cytokinetics Inc trades at $84.75 (market cap $11.62B). The key difference: Cytokinetics Inc is far larger — about 17.7× abrdn Income Credit Strategies Fund's market cap, and abrdn Income Credit Strategies Fund pays a 17.78% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| ACP | CYTK | |
|---|---|---|
Market Cap | $656.21M | $11.62B |
Sector | Financials | Technology |
52-Week High | $5.98 | $87.26 |
52-Week Low | $5.01 | $33.23 |
Dividend Yield | 17.78% | — |
Enterprise Value | — | $12.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACP trades at $5.25, down 0.57% today, with a neutral technical signal. The stock shows a low P/B of 0.89 and a high net income margin of 95.51% for 2024, though revenue declined from $79M in 2024 to $42M in 2025. Recent news highlights dividend declarations and a Seeking Alpha downgrade citing distribution sustainability concerns. Cash flow from operations was negative $81.31M in 2024, offset by financing inflows.
Outlook is mixed: valuation appears modest with a P/E near 16, but declining revenue and negative operating cash flow pose risks. The 17% distribution rate faces sustainability questions, while technical indicators suggest limited near-term momentum. Investors should weigh income potential against fundamental weaknesses and high beta exposure.
CYTK trades at $85.57, down 1.06% on the day, with a bullish technical signal from moving averages and strong analyst support. The company reported a net loss of $784.96 million in 2025, with revenue of $88.04 million, but recent news highlights the European launch of MYQORZO and upcoming clinical data presentations at the ESC Congress 2026, indicating growth potential.
The outlook for CYTK is driven by product launches and clinical milestones, but high valuation (P/S 98.09) and persistent losses pose risks. Analyst consensus is overwhelmingly bullish with a $110.60 price target, though investors must weigh the speculative nature against execution risks and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
